Clinical Trials on Recurrent Colon Cancer in Ireland

Total 1490 results

SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
University College Dublin
Mater Misericordiae University Hospital; Irish Cancer Society

Recruiting

COMpassion FOcused Therapy and Breathing Pattern REtraining After Cancer Recurrence (COMFORT)

Psychological Distress | Cancer Recurrence

Ireland
Cancer Trials Ireland

Recruiting

Breast Cancer Proteomics and Molecular Heterogeneity

Primary Breast Cancer | Recurrent/Metastatic Breast Cancer

Ireland
St Patrick's Hospital, Ireland

Terminated

Ketamine for Relapse Prevention in Recurrent Depressive Disorder (KINDRED)

Depression | Major Depressive Disorder | Relapse | Recurrent Depressive Disorder

Ireland
Dublin City University
Royal College of Surgeons, Ireland; Mater Misericordiae University Hospital

Active, not recruiting

Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy (PANO)

Ovarian Cancer | Colon Cancer | Appendix Cancer | Rectum Cancer | Peritoneal Malignancy

Ireland
Irish Clinical Outcomes in Research and Education
The Cleveland Clinic

Unknown

The 'SILVERMAN1' Trial Single Incision Laparoscopic Versus Existing Resection (Minimal Access) for Neoplasia (SILVERMAN 1)

Right Colon Tumors

Ireland
University of Colorado, Denver
Boston Scientific Corporation

Terminated

Salvage Cryotherapy in Recurrent Prostate Cancer (SCORE)

Recurrent Prostate Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy

Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer AJCC v7 | Stage III Liver Cancer | Stage IV Liver Cancer | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Stage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8

United States
St Vincent's University Hospital, Ireland
PelvEx collaborative

Not yet recruiting

PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting

Locally Advanced Rectal Cancer | Recurrent Rectal Cancer | Multidisciplinary Communication | Multidisciplinary Team Meeting (MDT) | Treatment Decisions

Ireland
Cancer Trials Ireland

Completed

Circulating miRNAs.

Breast Cancer | Recurrent Breast Cancer | Newly Diagnosed Breast Cancer

Ireland
Spexis AG

Terminated

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (FORTRESS)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

Spain, Belgium, United States, United Kingdom, Korea, Republic of, Taiwan, Italy, Russian Federation, Czechia, France, Brazil, Argentina, Ukraine
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm

United States
The Miriam Hospital

Completed

Promoting Physical Activity After Colorectal Cancer

Rectal Cancer | Colon Cancer

United States
Kiniksa Pharmaceuticals (UK), Ltd.

Completed

A Pilot Study of KPL-914 in Recurrent Pericarditis

Recurrent Pericarditis

United States
Imunon

Terminated

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) (ABLATE)

Colon Cancer Liver Metastasis

United States
St. James's Hospital, Ireland
Karolinska Institutet; St Mary's Hospital, Paddington, London

Completed

European iNvestigation of SUrveillance After Resection for Esophageal Cancer (ENSURE)

Esophageal Cancer | Chemoradiation | Chemotherapy | Surgery | Metastatic Cancer | Radiation | Recurrent Esophageal Cancer

Sweden, Ireland, United Kingdom
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IIA Rectal Cancer AJCC... and other conditions

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group

Completed

Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer

Stage III Colon Cancer | Adenocarcinoma of the Colon

United States, Canada, Puerto Rico
William Sikov MD
The Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode Island

Completed

Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)

Rectal Cancer | Colon Cancer

United States
St George's, University of London

Terminated

Intrauterine Levonorgestrel and Observation or Observation Alone in Preventing Atypical Endometrial Hyperplasia and Endometrial Cancer in Women With Hereditary Non-Polyposis Colorectal Cancer or Lynch Syndrome

Endometrial Cancer | Hereditary Non-polyposis Colon Cancer (hmsh2, hmlh1, hpms1, hpms2)

United Kingdom
Aadi Bioscience, Inc.

Recruiting

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

Cancer | Endometrial Cancer | Tumor | Recurrent Endometrial Carcinoma | Endometrioid Endometrial Cancer | Endometrioid Tumor

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer

Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Colon Adenocarcinoma | Stage IIA Colon Cancer AJCC v8

United States, Canada, Puerto Rico
UNICANCER
Canadian Cancer Trials Group; GONO GROUP

Active, not recruiting

IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting (IROCAS)

Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)

France, Canada
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
University of Washington
National Cancer Institute (NCI)

Completed

Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children

Melanoma | Lymphoma | Cervical Cancer | Leukemia | Breast Cancer | Rectal Cancer | Colon Cancer | Malignant Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
howard safran
The Miriam Hospital; Montefiore Medical Center; Rhode Island Hospital; Fatima Memorial...

Completed

A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer

Head and Neck Cancer | Colon Cancer

United States
PDS Biotechnology Corp.
Merck Sharp & Dohme LLC

Active, not recruiting

Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (VERSATILE002)

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Neoplasms, Head and Neck

United States, Puerto Rico, Ireland, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI); Natera, Inc.

Recruiting

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Stage III Colon Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Lynch Syndrome | Colon Mucinous Adenocarcinoma | Colon Signet Ring Cell Adenocarcinoma | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States, Canada, Puerto Rico, Peru, South Africa
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

Colon Cleansing

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
GOG Foundation
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7

United States, Canada, Japan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Psychological Impact of Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

Recurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Carcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus Cancer | Stage IIIC1 Uterine Corpus Cancer | Stage IIIC2 Uterine Corpus Cancer

United States

Clinical Trials on Recurrent Colon Cancer in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations